| For: | Pejčić AV. Targeting muscarinic receptors in schizophrenia treatment: Novel antipsychotic xanomeline/trospium chloride. World J Psychiatry 2025; 15(6): 105409 [PMID: 40574777 DOI: 10.5498/wjp.v15.i6.105409] |
|---|---|
| URL: | https://www.wjgnet.com/2220-3206/full/v15/i6/105409.htm |
| Number | Citing Articles |
| 1 |
Leslie Citrome. What’s in a name? What shall we call xanomeline-trospium combination?. Expert Opinion on Drug Safety 2026; 25(7) doi: 10.1080/14740338.2025.2588631
|
| 2 |
Yining Zeng, Xueting Wang, Hao Wu, Xiyue Tan, Ruixia Wang, Yuxia Liu, Junguo Duan. Post-marketing safety surveillance of the novel muscarinic antipsychotic Xanomeline-Trospium for schizophrenia: A comparative disproportionality analysis against olanzapine based on FAERS data. Psychiatry Research 2026; 364 doi: 10.1016/j.psychres.2026.117270
|
| 3 |
Nahi Sabih Alruwaili, Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Mustafa M. Shokr, Neda M. Bogari, Suhair Alhelfawi, Mubarak Alruwaili, Gaber El-Saber Batiha. Beyond categorical boundaries: Common molecular and cellular pathways in autism spectrum disorder and schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2026; 148 doi: 10.1016/j.pnpbp.2026.111774
|